Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary rh-proUK and nicorandil during primary PCI for STEMI
ChiCTR1800015932Phase 4Recruiting
- Sponsor
- Jiangxi Provincial People's Hospital
- Start
- May 2018
- Modality
- Small Molecules, Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human prourokinase and nicorandil in myocardial infarction (MI) (4 arms), sponsored by Jiangxi Provincial People's Hospital. Primary endpoints: Post-procedural TIMI flow grade, Corrected TIMI frame count and 6 more. Started May 2018; status: recruiting.
02
Drugs
recombinant human prourokinasenicorandil
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR1800015932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015932.